Remodulin (United Therapeutics/Mochida) contains treprostinil, which is a prostaglandin analog that functions as a prostaglandin I2 receptor agonist. This leads to potent vasodilation of the pulmonary arteries and inhibition of platelet aggregation.
Remodulin (treprostinil; United Therapeutics/Mochida) is a last-line treatment option for more severe patients. Despite Remodulin’s subcutaneous formulation reducing the risk of severe sepsis and thromboembolism associated with other intravenously administered prostacyclin analogs, injection site pain and site reactions remain a barrier to the drug’s uptake. Accordingly, United Therapeutics is developing three new formulations of Remodulin to overcome administration difficulties. The complexity of Remodulin’s administration and the introduction of a novel implantable pump developed in collaboration with Medtronic may provide a sustained market for Remodulin despite facing generic competition from 2018. Furthermore, United Therapeutics’ defensive acquisition of SteadyMed has enabled the company to circumvent potential competition from SteadyMed’s pipeline asset Trevyent, which is a PatchPump with treprostinil for subcutaneous treatment of pulmonary arterial hypertension (PAH).
LIST OF FIGURES
8 Figure 1: Remodulin for pulmonary hypertension – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Remodulin for pulmonary hypertension
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Remodulin for pulmonary hypertension
12 Figure 4: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country, 2016–25
LIST OF TABLES
5 Table 1: Remodulin drug profile
7 Table 2: Remodulin pivotal trial data in pulmonary hypertension
13 Table 3: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.